Cardiomyopathy - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 52 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Cardiomyopathy - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Cardiomyopathy - Pipeline Review, H2 2014', provides an overview of the Cardiomyopathy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cardiomyopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cardiomyopathy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cardiomyopathy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Cardiomyopathy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Cardiomyopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cardiomyopathy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cardiomyopathy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cardiomyopathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Cardiomyopathy Overview 7
Therapeutics Development 8
Pipeline Products for Cardiomyopathy - Overview 8
Pipeline Products for Cardiomyopathy - Comparative Analysis 9
Cardiomyopathy - Therapeutics under Development by Companies 10
Cardiomyopathy - Therapeutics under Investigation by Universities/Institutes 12
Cardiomyopathy - Pipeline Products Glance 13
Early Stage Products 13
Unknown Stage Products 14
Cardiomyopathy - Products under Development by Companies 15
Cardiomyopathy - Products under Investigation by Universities/Institutes 16
Cardiomyopathy - Companies Involved in Therapeutics Development 17
Shire Plc 17
Torrent Pharmaceuticals Limited 18
LG Life Sciences, Ltd. 19
Genethon 20
Beech Tree Labs, Inc. 21
Nyken BV 22
Cardiomyopathy - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
LC-280126 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Recombinat Proten to Antagonize Interleukin-1 Receptor for Cardiomyopathy and Ischemia Reperfusion Injury - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
GLP-1 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
NYK-1112 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
SHP-627 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Cyndacel-M - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Peptides for Duchenne Muscular Dystrophy and Cardiac Disease - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
MG-132 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Gene Therapy for Cardiomyopathy - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
TRC-120038 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
JR-100 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
LUNAR-101 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Gene Therapy For Cardiomyopathy - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Drug for Cardiomyopathy - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Cardiomyopathy - Recent Pipeline Updates 47
Cardiomyopathy - Dormant Projects 49
Cardiomyopathy - Product Development Milestones 50
Featured News & Press Releases 50
Sep 16, 2013: Aastrom Clinical Trial Application for Phase 2b ixCELL-DCM Study of ixmyelocel-T Approved in Canada 50
Jun 26, 1995: Zinecard receives marketing clearence. 50
Dec 12, 1994: Zinecard had been recommended for approval by FDA advisory committee. 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52

List of Tables
Number of Products under Development for Cardiomyopathy, H2 2014 8
Number of Products under Development for Cardiomyopathy - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Number of Products under Investigation by Universities/Institutes, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Comparative Analysis by Unknown Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Products under Investigation by Universities/Institutes, H2 2014 16
Cardiomyopathy - Pipeline by Shire Plc, H2 2014 17
Cardiomyopathy - Pipeline by Torrent Pharmaceuticals Limited, H2 2014 18
Cardiomyopathy - Pipeline by LG Life Sciences, Ltd., H2 2014 19
Cardiomyopathy - Pipeline by Genethon, H2 2014 20
Cardiomyopathy - Pipeline by Beech Tree Labs, Inc., H2 2014 21
Cardiomyopathy - Pipeline by Nyken BV, H2 2014 22
Assessment by Monotherapy Products, H2 2014 23
Number of Products by Stage and Target, H2 2014 25
Number of Products by Stage and Mechanism of Action, H2 2014 27
Number of Products by Stage and Route of Administration, H2 2014 29
Number of Products by Stage and Molecule Type, H2 2014 31
Cardiomyopathy Therapeutics - Recent Pipeline Updates, H2 2014 47
Cardiomyopathy - Dormant Projects, H2 2014 49